Horst Olschewski (Graz, Austria), Frederic Perros (Le Plessis-Robinson, France), Robin Condliffe (Sheffield, United Kingdom), John Wort (Hampton, United Kingdom)
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Kelly Chin (Dallas, United States of America), Kelly Chin, Richard Channick, Aryeh Fischer, Robert Frantz, Mardi Gomberg-Maitland, Leah Kleinman, Chad Miller, Elke Hunsche, Rohan Zamanian, David Badesch
|  |
Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
Gabor Kovacs (Graz, Austria), Gabor Kovacs, Alexander Avian, Philipp Douschan, Vasile Foris, Andrea Olschewski, Horst Olschewski
| |
Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Nicola Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne, Andrea Huppertz, Alexandra Carls, Walter-Emil Haefeli, Ekkehard Grünig
| |
Pharmacokinetic interactions in different combinations of pulmonary arterial hypertension treatment
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Satenik Harutyunova, Nicola Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne, Christian Nagel, Andrea Huppertz, Alexandra Carls, Walter-Emil Haefeli, Ekkehard Grünig
| |
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution
Carlos Fernandez (Bridgewater, United States of America), David Han, Carlos Fernandez, Eugene Sullivan, Danlin Xu, Walter Perkins, Mona Darwish, Chris Rubino
|  |
Response to treatment assessment in patients with PAH by MRI based computational modelling
Angela Lungu (Sheffield, United Kingdom), Angela Lungu, Rod Hose, David Capener, David Kiely, Jim Wild, Andrew Swift
| |
Physical activity (PA) in pulmonary arterial hypertension (PAH) can be predicted by questionnaire
Benjamin Garfield (London, United Kingdom), Benjamin Garfield, Dongmin Shao, Richard Paul, Lisa Parfitt, Carl Harries, Laura Price, Paul Kemp, Michael Polkey, John Wort
| |
Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT
Marc Humbert (Le Kremlin-Bicêtre, France), Marc Humbert, Hossein-Ardeschir Ghofrani, Dennis Busse, Janethe de Olivereira Pena, David Langleben
| |
An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme
Laura Moth (London, United Kingdom), Laura Moth, Lauren Hogg, Lynn McDonnell, Meera Patel, Philip Marino
| |
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009)
Carlos Fernandez (Bridgewater, United States of America), David Han, Carlos Fernandez, Eugene Sullivan, Danlin Xu, Walter Perkins, Mona Darwish, Chris Rubino
| |
Improving identification and early referral of pulmonary hypertension patients
Lola Loewenthal (London, United Kingdom), Lola Loewenthal, Emily Shaw, Brendan Madden
| |
Prognostic impact of oxygen saturation during the 6-minute walk test in pulmonary arterial hypertension
Mario Santos (Porto, Portugal), Mario Santos, Ines Furtado, Fabienne Goncalves, Luisa Carvalho, Abilio Reis
| |
Treatment of pulmonary arterial hypertension in elderly and very elderly patients
Marylise Ginoux (Ste Colombe, France), Marylise Ginoux, Ségolène Turquier, Julie Traclet, Chahera Khouatra, Francois Philit, Agathe Senechal, Jean-Charles Glerant, Jean-Francois Mornex, Jean-Francois Cordier, Vincent Cottin
| |
A pilot study of digital feedback to guide therapeutic decisions in pulmonary hypertension
Paul A. Corris (Newcastle, United Kingdom), Paul A. Corris, Margaret Day, Maxsim Gibiansky, Yoona A. Kim, Lorenzo DiCarlo
| |
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry
Henning Gall (Giessen, Germany), Henning Gall, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Ekkehard Grünig, Michael Halank, Hans Klose, Jean-Luc Vachiéry, Hubert Wirtz, Tobias Lange, Repke J. Snijder, Silvia Ulrich, Ralf Ewert, Iraklis Tsangaris, Joanna Pepke-Zaba, Irene Lang, Judith Löffler-Ragg, Vincent Cottin, Anco Boonstra, Sean Gaine, Paul A. Corris, Andrew Peacock, Gérald Simonneau, Miguel-Angel Gómez Sánchez, Jens Klotsche, David Pittrow, Christian Meier, Monika Brunn, Marc Humbert
| |
Embolisation of pulmonary arteriovenous malformations improves nosebleeds in people with hereditary haemorrhagic telangiectasia
Claire Shovlin (London, United Kingdom), Claire Shovlin, Trishan Patel, James Jackson
| |
Exhaled nitric oxide levels in patients with pulmonary hypertension
Gulfer Okumus (Istanbul, Turkey), Gulfer Okumus, Zuleyha Bingol, Nilay Orak, Esen Kiyan, Ekrem Bilal Karaayvaz, Ahmet Kaya Bilge, Halim Issever
| |
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Joan Albert Barbera (Barcelona, Spain), Joan Albert Barbera, Nazzareno Galie, Adaani Frost, Hossein Ardeschir Ghofrani, Marius Hoeper, Vallerie Mclaughlin, Andrew Peacock, Gerald Simonneau, Jean-Luc Vachiery, Christiana Blair, Karen Miller, Julia Harris, Jonathan Langley, Lewis Rubin
| |
miR-424 and muscle wasting in pulmonary arterial hypertension
Benjamin Garfield (London, United Kingdom), Martin Connolly, Benjamin Garfield, Alexi Crosby, Peiran Yang, Nicholas Morrell, Michael Polkey, S. John Wort, Paul Kemp
| |
Reactive oxygen species production by rat neutrophils in pulmonary arterial hypertension experimental model
Galina Semenkova (Minsk, Belarus), Galina Semenkova, Igor Adzerikho, Olga Yatsevich
| |